Belviq is competing against the anti-obesity drug Qsymia
Belviq is competing against the anti-obesity drug Qsymia, which is also available. Lief isn't bothered by that. "No single drug is sufficient for all indications, so I think the market is quite large," he said. "Obesity or people who are overweight account for about half of the adult population, so I think we'll have a very, very good opportunity," Lief said.
(Watch: No Dent in Sales on Economic Uncertainties)
To better market Belviq, Arena has partnered with Eisai, the Japanese company best known for producing Aricept, the $2 billion Alzheimer's drug still used today, and gastrointestinal drug Aciphex.
"They have about 10 drugs that they've been successful with, and we look forward to Belviq being quite successful, too," Lief said.
It's actually simple, obesity is a leading cause for many disease not just diabetes. Over weight will end up being the spark for cancer etc etc etc. This market will be very large as long as the drug is safe. The hard part is done, FDA approval, not it will get easy unless you read every post on the message boards